Stocks Health care MOLN
NASDAQ · Health careMolecular Partners AG (MOLN)
Molecular Partners AG reported revenue of CHF 0 in fiscal 2025, down 100.0% from a year earlier. It posted a net loss of CHF 61.7M. In fiscal 2025 capital spending exceeded operating cash flow by CHF 52M. At December 31, 2025 it held CHF 82.7M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 12, 2026.
Key facts about Molecular Partners AG
- Net worth
- Molecular Partners AG has a market value (market cap) of $124.7M at the latest share price, and shareholders' equity of CHF 80.3M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was CHF 0 (-100.0% year on year), with a net loss of CHF 61.7M.
- Cash flow
- In fiscal 2025 operations used CHF 51.3M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 12, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Molecular Partners AG does
Molecular Partners AG is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MOLN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | CHF 0 | -CHF 61.7M | -CHF 1.65 | -CHF 52M |
| 2024 | CHF 5M | -CHF 54M | -CHF 1.59 | -CHF 60M |
| 2023 | CHF 7M | -CHF 62M | -CHF 1.89 | -CHF 59.6M |
| 2022 | CHF 189.6M | CHF 117.9M | CHF 3.54 | CHF 117.4M |
| 2021 | CHF 9.8M | -CHF 63.8M | -CHF 2.06 | -CHF 91.9M |
| 2021 | CHF 9.3M | -CHF 62.8M | -CHF 2.51 | -CHF 30.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Molecular Partners AG has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026
- August 25, 2026
- July 20, 2026
- July 7, 2026
- July 2, 2026
- June 24, 2026
- June 1, 2026
- May 12, 2026
- May 1, 2026
- April 14, 2026
Insider trades
What the people running Molecular Partners AG did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns MOLN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 10.6% | May 2, 2025 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC13G, passive | 5.8% | July 17, 2025 |
Largest institutional holders
Insiders
Questions about MOLN
What does Molecular Partners AG do?
Molecular Partners AG is a company in the Health care sector, listed on NASDAQ as MOLN. Its shares trade on NASDAQ under the ticker MOLN.
What is Molecular Partners AG's net worth?
Molecular Partners AG has a market value (market cap) of $124.7M at the latest share price, and shareholders' equity of CHF 80.3M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Molecular Partners AG profitable?
No. In fiscal 2025 it reported a net loss of CHF 61.7M.
How much revenue does Molecular Partners AG make?
In fiscal 2025 Molecular Partners AG reported revenue of CHF 0. That is 100.0% less than a year earlier.
When did Molecular Partners AG last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 12, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from October 29, 2026.
Similar companies
Compare MOLN with
Follow MOLN
Get an email when Molecular Partners AG files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Molecular Partners AG tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.